Another team showed that poly (dl-lactic-co-glycolic acid) NPs decorated with synthetic citrullinated peptide and complement-activating lytic peptide could significantly reduce the ACPA production of B cells from peptide seropositive RA patients, indicating a potential to specifically target and deplete autoreactive B-cells for RA treatment [129]. The gene discussed is PRTN3; the disease is rheumatoid arthritis.